GEHC Stock Up on $500M Strategic Care Alliance With Catholic Health
GE HealthCare's shares rise about 4% after unveiling a $500M, 10-year alliance to deploy 1,300 technologies across Catholic Health.
GEHC - GE HealthCare Technologies Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$78.58
DETAILS
HIGH:
$90.00
LOW:
$65.00
MEDIAN:
$80.00
CONSENSUS:
$78.58
UPSIDE:
24.59%
Stock News
Catholic Health and GE HealthCare partner to expand patient access across Long Island
ROCKVILLE CENTRE, N.Y.--(BUSINESS WIRE)--Catholic Health, an integrated health system located on Long Island, NY, and GE HealthCare (Nasdaq: GEHC) announced today a 10-year strategic partnership, known as a Care Alliance, valued at approximately $500 million, to help expand access to advanced imaging, precision diagnostics and AI-enabled technology across Catholic Health in support of innovative, compassionate and patient-centered care. This will be one of the largest Care Alliances between GE.
Do Options Traders Know Something About GE HealthCare Stock We Don't?
Investors need to pay close attention to GEHC stock based on the movements in the options market lately.
GE HealthCare & Mayo Clinic Unite to Advance Cancer Theranostics
GEHC and Mayo Clinic collaboration aims to advance adaptive cancer theranostics using imaging, biomarkers and clinical data from the MI-BET study.
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, July 8, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC.
GE HealthCare and Mayo Clinic aim to advance personalized cancer treatment through new theranostics research collaboration
CHICAGO & ROCHESTER, Minn.--(BUSINESS WIRE)--GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. This collaboration is a direct result of the 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of.
GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa., July 8, 2026 /PRNewswire/ -- Law Offices of Howard G.
GE HealthCare to announce second quarter 2026 results on July 29, 2026
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will.
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES, July 7, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ: GEHC) on behalf of investors concerning the Company's possible violations of federal securities laws.
GE HealthCare announces cash dividend for second quarter of 2026
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2026 payable on August 14, 2026, to all shareholders of record as of July 24, 2026.About GE HealthCare Technologies Inc.GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle.
GEHC Launches Allia Upgrade Pathways for Interventional Suites
GE HealthCare's Allia upgrade pathways let providers modernize legacy imaging systems with AI-enabled workflows while reducing construction and disruption.
GE HealthCare introduces Allia upgrade pathways designed to modernize existing interventional suites
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced Allia™ platform upgrade pathways designed to help customers modernize select legacy Innova™ and Discovery™ Image Guiding Solutions (IGS) systems. These pathways provide access to Allia technologies and workflows that support efficiency and procedural decision-making while helping preserve existing infrastructure, avoid major construction work, extend interventional room lifetime, and minimize disruption to clinical operations. As procedura.
Here Are Tuesday's Best Wall Street Analyst Research Calls: Centene, Darden Restaurants, Flutter Entertainment, GE Healthcare, IBM, Nike, SpaceX, Synopsys, Target, and More
Futures are trading lower after a mixed start to trading on Monday, following the holiday-shortened week due to the Juneteenth Federal holiday.
GEHC Expands Carilion Tie to Enhance Patient Care Across Virginia
GE HealthCare expands its Carilion Clinic collaboration with AAMP and Encompass to improve equipment management and operational efficiency across Virginia.
GE HealthCare advancing enterprise imaging with cloud-enabled solutions
CHICAGO--(BUSINESS WIRE)--GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging Informatics in Medicine (SIIM) 2026 Annual Meeting in Pittsburgh, PA. Medical imaging departments today are under immense pressure from all sides including rising imaging volumes and increasing case complexity, while staffing shortages continue to grow. According to the American College of Radiology (ACR), radiologist workforce shortages have been identified as the biggest th.
GE HealthCare Gains FDA Clearance for AI Radiation Planning Software
GEHC wins FDA clearance for AI-powered radiation planning software, adding new clinical models and a pathway for faster future updates.
GE HealthCare receives FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, advancing AI-enabled radiation therapy planning with expanded clinical capabilities
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for MIM Contour ProtégéAI+™ 2.0, an AI-enabled auto-contouring software to assist radiation oncology care teams with treatment planning. This can help clinicians reduce treatment planning time, enabling them to focus on delivering more timely and personalized care for patients. The FDA clearance includes a Predetermined Change Control.
GE HealthCare Technologies Inc. (GEHC) Presents at Jefferies Global Healthcare Conference 2026 Transcript
GE HealthCare Technologies Inc. (GEHC) Presents at Jefferies Global Healthcare Conference 2026 Transcript
GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations
CHICAGO--(BUSINESS WIRE)--As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operations while improving diagnostic confidence and workflow efficiency. At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare showcases its latest technologies and AI-enabled workflows to help support precision care across care pathways. Nuclear medicine is undergoing rap.
GE HealthCare Technologies: Doing Some Bottom Fishing
GE HealthCare Technologies: Doing Some Bottom Fishing
Price Targets
GE HealthCare price target lowered to $67 from $69 at UBS
$67.00
(was $64.23)
UBS
GE HealthCare price target lowered to $75 from $80 at BTIG
$75.00
(was $64.70)
Ryan Zimmerman
·
BTIG
GE HealthCare initiated with a Market Perform at BMO Capital
$70.00
(was $64.68)
BMO Capital
GE HealthCare initiated with an Outperform at RBC Capital
$80.00
(was $60.64)
RBC Capital
UBS Upgrades GE HealthCare (GEHC) to Neutral
$69.00
(was $64.26)
Graham Doyle
·
UBS
GE HealthCare price target lowered to $80 from $85 at Evercore ISI
$80.00
(was $59.81)
Evercore ISI
GE HealthCare price target lowered to $85 from $89 at Oppenheimer
$85.00
(was $60.03)
Suraj Kalia
·
Oppenheimer
GE HealthCare price target lowered to $78 from $87 at Barclays
$78.00
(was $59.48)
Matt Miksic
·
Barclays
GE HealthCare downgraded to Neutral from Buy at Goldman Sachs
$65.00
(was $59.48)
David Roman
·
Goldman Sachs
GE HealthCare price target lowered to $80 from $98 at Stifel
$80.00
(was $60.06)
Stifel Nicolaus
GE HealthCare price target lowered to $88 from $96 at Piper Sandler
$88.00
(was $73.20)
Piper Sandler
GE HealthCare price target lowered to $90 from $95 at Mizuho
$90.00
(was $72.69)
Mizuho Securities
GE HealthCare price target raised to $87 from $86 at Barclays
$87.00
(was $82.31)
Barclays
GE HealthCare (GEHC) PT Raised to $98 at Stifel
$98.00
(was $82.63)
Rick Wise
·
Stifel Nicolaus
GE HealthCare price target raised to $85 from $80 at Morgan Stanley
$85.00
(was $82.63)
Morgan Stanley
GE HealthCare (GEHC) PT Raised to $91 at BTIG
$91.00
(was $83.69)
Ryan Zimmerman
·
BTIG
GE HealthCare price target raised to $94 from $91 at Piper Sandler
$94.00
(was $78.78)
Piper Sandler
GE HealthCare downgraded to Sell from Neutral at UBS
$77.00
(was $85.30)
UBS
GE HealthCare price target raised to $98 from $86 at Goldman Sachs
$98.00
(was $88.16)
Goldman Sachs
GE HealthCare price target raised to $95 from $90 at Stifel
$95.00
(was $86.73)
Stifel Nicolaus